Likewise, the use of isogenic NRAS mutant-A375 melanoma cell lines is firmly established, and the commercial availability of these lines enables the explorative molecular examination of genetic mechanisms underlying BRAF kinase inhibitor resistance and the BRAF RAS–RAF–MEK–ERK (MAPK) signaling pathway in melanoma [44]. The gene discussed is BRAF; the disease is melanoma.